Our results consistently showed that JBT19 human sarcoma cells stably express PD-L1, can in vivo produce high-content collagen tumors, and ex vivo be used to produce LAIR-1+ JBT19-reactive lymphocytes. Here, CD274 is linked to sarcoma.